2020-2027 Analysis and Review Macrophage Stimulating Protein Receptor Market

Macrophage Stimulating Protein Receptor Market

Macrophage Stimulating Protein Receptor Market By Clinical Application (Non-Small Cell Lung Cancer, Osteoporosis and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

11-03-2020 REP-HC-5048 40 Tables 116 pages Format

The macrophage stimulating protein receptor market was valued at USD7,278.3Mn by 2019. According to the latest statistics provided by the World Health Organization (WHO), in 2018, approximately 2.1 million new cases of lung cancer were reported throughout the globe. Rising prevalence of metastatic cancer cases associated with macrophage stimulating protein receptor signaling pathways and the development of a strong drug pipeline for its treatment in the near future together drive its market growth.

 Macrophage Stimulating Protein Receptor Market

Macrophage stimulating protein receptor in the human beings is encoded by the gene MSTR1 and is also called as Recepteur d'Origine Nantais or RON kinase and is related to the C-met tyrosine kinase receptors. Its signaling pathway is being targeted to develop potential small-molecule antineoplastic drugs such as crizotinib, ASLAN-005, BMS-777607, AL-2846, denosumab, etc.

The major segments related to the macrophage stimulating protein receptor market are:

By Clinical Application (2017–2027; US$ Mn)

Non-Small Cell Lung Cancer

Osteoporosis

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global macrophage stimulating protein receptor market
  • The overall segmentation of the macrophage stimulating protein receptor market, clinical application, distribution channel, and geography is minutely studied. Non-small cell lung cancer and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
  • Rising prevalence of non-small cell lung cancer and osteoporosis in female population together drive the macrophage stimulating protein receptors market
  • Proactive research and development and led to the generation of the strong product pipeline 

Report gist?

  • The study of the global macrophage stimulating protein receptor market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
  • The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

  • This study is suitable for industry participants and stakeholders in the biopharmaceutical companies engaged in manufacturing and marketing of drugs pertaining to macrophage stimulating protein receptors which is gaining huge demand owing to rising prevalence of non-small cell lung cancer and osteoporosis worldwide
  • The report will benefit researchers engaged in the drug development for the clinical applications associated with macrophage stimulating protein receptor
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to macrophage stimulating protein receptor market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies

Segment Analysis

Non-small cell lung cancer (NSCLC) is spearheading the clinical application segment for macrophage stimulating protein receptor market. It comprises 80 to 85% of all known lung cancer cases reported worldwide. It is highly heterogeneous at the molecular level and receptor tyrosine kinase and MET frequently cause mutations that promote lung tumorigenesis. Tyrosine kinase inhibitors are being developed for treating NSCLC by targeting the mutations happening at the receptor level. Osteoporosis is going to register rampant market growth during the forecast period due to the association of macrophage stimulating protein signaling pathway causing the elevation in the number of breast cancer in women and simultaneously promoting the osteolytic bone metastasis respectively. Monoclonal antibodies are being developed to treat cancer-induced osteoporosis by preventing the development of osteoclasts.

Hospital pharmacy is currently reigning the distribution channel segment for macrophage stimulating protein receptors market. Hospital pharmacist is essential for compounding antineoplastic drug molecules for the treatment of metastatic cancer patients taking cognizance of precise drug posology in accordance with the physician’s prescription. Retail pharmacy will be the fastest-growing segment during the forecast period owing to the provision of antineoplastic drugs at subsidized rates primarily funded by the healthcare agencies worldwide.

North America is presently dominating the geography segment for macrophage stimulating protein receptor market. As per the research citings provided by the American Society for Clinical Oncology (ASCO), in 2019 approximately 228,820 U.S. citizens were diagnosed with lung cancer. Further detailed investigation reported that non-small cell lung cancer represented 85% of the diagnosed cases. Domicile of key players such as Amgen, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, etc. further propel the market growth in the region. The market growth strategy adopted in the European region is a strategic collaboration between academic research institutes and biopharmaceutical companies to develop tyrosine kinase receptor inhibitors for the treatment of osteoporosis in women population. Additionally, a favorable reimbursement scenario for drugs working on the macrophage stimulating protein receptor for treating metastatic cancer accentuates its market growth. Asia Pacific is keen to register rapid market growth owing to the significant rise in the number of patients diagnosed with NSCLC and developing healthcare infrastructure.

Select License Type

$4,600
$6,600
$9,500

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.